Integra LifeSciences (NASDAQ:IART – Get Free Report) updated its FY 2026 earnings guidance on Wednesday morning. The company provided earnings per share (EPS) guidance of 2.400-2.500 for the period, compared to the consensus estimate of 2.450. The company issued revenue guidance of $1.7 billion-$1.7 billion, compared to the consensus revenue estimate of $1.7 billion. Integra LifeSciences also updated its Q3 2026 guidance to 0.530-0.610 EPS.
Analyst Ratings Changes
A number of analysts recently commented on the company. UBS Group began coverage on Integra LifeSciences in a research report on Tuesday. They issued a “neutral” rating and a $19.00 target price for the company. Argus raised Integra LifeSciences from a “hold” rating to a “buy” rating and set a $25.00 price objective for the company in a research note on Thursday, June 18th. Wells Fargo & Company raised their price objective on Integra LifeSciences from $15.00 to $18.00 and gave the company an “equal weight” rating in a research note on Thursday. Wall Street Zen lowered Integra LifeSciences from a “strong-buy” rating to a “buy” rating in a research report on Saturday, July 18th. Finally, Weiss Ratings upgraded Integra LifeSciences from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, May 13th. One analyst has rated the stock with a Buy rating, five have given a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat.com, Integra LifeSciences currently has an average rating of “Reduce” and a consensus price target of $18.86.
Check Out Our Latest Analysis on Integra LifeSciences
Integra LifeSciences Stock Up 7.4%
Integra LifeSciences (NASDAQ:IART – Get Free Report) last announced its earnings results on Wednesday, July 29th. The life sciences company reported $0.56 EPS for the quarter, beating the consensus estimate of $0.48 by $0.08. Integra LifeSciences had a negative net margin of 30.15% and a positive return on equity of 17.42%. The company had revenue of $418.76 million during the quarter, compared to the consensus estimate of $417.54 million. Integra LifeSciences has set its Q3 2026 guidance at 0.530-0.610 EPS and its FY 2026 guidance at 2.400-2.500 EPS. Equities analysts predict that Integra LifeSciences will post 2.45 earnings per share for the current year.
Key Integra LifeSciences News
Here are the key news stories impacting Integra LifeSciences this week:
- Positive Sentiment: Integra reported second-quarter earnings of $0.56 per share, above the $0.48 analyst consensus and up from $0.45 a year earlier. Revenue of $418.8 million was essentially in line with estimates. Integra LifeSciences Reports Second Quarter 2026 Financial Results
- Positive Sentiment: Wells Fargo raised its price target for IART from $15 to $18. Although the firm maintained an “equal weight” rating, the higher target reflects improved valuation support and leaves modest additional upside from recent trading levels. Wells Fargo Raises Integra LifeSciences Price Target
- Positive Sentiment: Technical screens identified Integra as a potential breakout stock trading near its 52-week high, suggesting continued momentum could attract additional buyers. Stocks Showing Breakout Potential
- Neutral Sentiment: Management guided to third-quarter EPS of $0.53-$0.61 and revenue of $410 million-$425 million, broadly consistent with Wall Street expectations. Full-year EPS guidance of $2.40-$2.50 also brackets the $2.45 consensus, limiting the potential for a major estimate-driven re-rating. Integra LifeSciences Second-Quarter Results
- Neutral Sentiment: UBS began coverage of Integra, adding fresh institutional research coverage; the available report does not specify its rating or price target. UBS Begins Coverage on Integra LifeSciences
Institutional Trading of Integra LifeSciences
A number of hedge funds have recently bought and sold shares of the business. Osaic Holdings Inc. boosted its position in Integra LifeSciences by 36.6% in the second quarter. Osaic Holdings Inc. now owns 4,119 shares of the life sciences company’s stock worth $51,000 after purchasing an additional 1,104 shares during the last quarter. State of Tennessee Department of Treasury increased its position in shares of Integra LifeSciences by 7.9% during the 4th quarter. State of Tennessee Department of Treasury now owns 26,745 shares of the life sciences company’s stock valued at $332,000 after purchasing an additional 1,964 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in shares of Integra LifeSciences by 5.1% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 40,441 shares of the life sciences company’s stock valued at $889,000 after purchasing an additional 1,975 shares during the last quarter. Capital Fund Management S.A. raised its stake in shares of Integra LifeSciences by 5.7% during the 3rd quarter. Capital Fund Management S.A. now owns 37,322 shares of the life sciences company’s stock worth $535,000 after purchasing an additional 1,997 shares during the period. Finally, Global Retirement Partners LLC bought a new stake in shares of Integra LifeSciences during the 4th quarter worth $25,000. 84.78% of the stock is currently owned by institutional investors.
About Integra LifeSciences
Integra LifeSciences Corporation is a global medical technology company specializing in products and innovations for neurosurgery, regenerative medicine and reconstructive procedures. The company develops and markets surgical instruments, implants and advanced wound care solutions designed to support tissue repair and functional recovery. Its product portfolio includes collagen-based matrices, dural substitutes, hemostatic agents and specialized spinal and peripheral fixation devices.
Founded in 1989 and headquartered in Plainsboro, New Jersey, Integra has expanded its capabilities through targeted acquisitions and internal research efforts.
Read More
- Five stocks we like better than Integra LifeSciences
- Tesla: After a Rough Quarter, 2 Very Different Futures Come Into Focus
- Why NXP Semiconductors Could Be the AI Stock Everyone Is Missing
- Powering Up: NextEra and Brookfield Build an Off-Grid Empire
- DoorDash’s Drone Certification Could Reshape Its Delivery Margins
Receive News & Ratings for Integra LifeSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra LifeSciences and related companies with MarketBeat.com's FREE daily email newsletter.
